It has been shown that an EZH2 over-expression can lead to subsequent up-regulation of targeted genes involved in SCLC tumorigenesis as ASCL1, suggesting that EZH2 targeting could represent a promising therapeutic strategy in this setting [38,39]. The gene discussed is EZH2; the disease is small cell lung carcinoma.